The role of estrogen receptor alpha in breast cancer cell proliferation mediated by progestins;El receptor de estrógenos alfa como mediador del efecto proliferativo de progestágenos en cáncer de mama

Medicina (Argentina)

Volumn 72, Issue 4, 2012, Pages 315-320

  Lanari, Claudia ^a   Giulianelli, Sebastián ^a   Vaqué, José P ^b   Wargon, Victoria ^a   Soldati, Rocío ^a   Vanzulli, Silvia I ^c   Martins, Rubén ^d   Zeitlin, Eduardo ^d   Helguero, Luisa ^e   Lamb, Caroline ^a   Molinolo, Alfredo A ^b   Gutkind, J Silvio ^b  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^c ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^d Policlinico Bancario   (Argentina)

^e UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

Breast cancer; CCND1 MYC; ER ; MPA; PR

Indexed keywords

CCND1 PROTEIN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MEMBRANE PROTEIN; MYC PROTEIN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; ASSAY; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER REGRESSION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; DUOLINK ASSAY; GENE CONTROL; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOTHESIS; INHIBITION KINETICS; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROMOTER REGION; RECEPTOR BINDING;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CYCLIN D1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENES, MYC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MEDROXYPROGESTERONE ACETATE; MURINAE; PROGESTINS; RECEPTORS, PROGESTERONE; TRANSCRIPTION, GENETIC;

EID: 84865119810     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Lange CA, Sartorius CA, Abdel-Hafz H, et al. Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol 2008; 630: 94-111.
2. Lanari C, Lamb CA, Fabris VT, et al. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 2009; 16: 333-350.
3. Lamb CA, Helguero LA, Fabris V, Colombo L, Molinolo AA, Lanari C. Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma. Breast Cancer Res Treat 2003: 79: 25-35.
4. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978; 103: 1742-1751.
5. Migliaccio A, Piccolo D, Castoria G, et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 1998; 17: 2008-2018.
6. Ballaré C, Uhrig M, Bechtold T, Sancho E, et al. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 2003; 23: 1994-2008.
7. Boonyaratanakornkit V, Scott MP, Ribon V, et al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 2001; 8: 269-280.
8. Moore MR, Zhou JL, Blankenship KA, Strobl JS, Edwards DP, Gentry RN. A sequence in the 5' flanking region confers progestin responsiveness on the human c-myc gene. J Steroid Biochem Mol Biol 1997; 62: 243-252.
9. Musgrove EA, Hamilton JA, Lee CS, Sweeney KJ, Watts CK, Sutherland RL. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993; 13: 3577-3587.
10. Nishino Y, Schneider MR, Michna H. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384. J Cancer Res Clin Oncol 1994; 120: 298-302.
11. Wargon V, Helguero LA, Bolado J, et al. Reversal of anti-progestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas. Breast Cancer Res. Treat 2009; 116: 449-460.
12. Cerliani JP, Guillardoy T, Giulianelli S. Interaction between FGFR-2, STAT5, and Progesterone Receptors in Breast Cancer. Cancer Res 2011; 71: 3720-3731.
13. Quiles I, Millán-Ariño L, Subtil-Rodríguez A, et al. Mu-tational analysis of progesterone receptor functional domains in stable cell lines delineates sets of genes regulated by different mechanisms. Mol Endocrinol 2009; 23: 809-826.
14. Cicatiello L, Addeo R, Sasso A, et al. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 2004; 24: 7260-7274.
15. Beguelin W, Díaz Flaque MC, Proietti CJ, et al. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol 2010; 30: 5456-5472.